Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical heart valves and minimally invasive valve therapy—one of the hottest areas in cardiac devices.
Edwards' efforts to focus on efficiency and higher-margin products have paid off, as gross margins increased from 47% in 2000 to 78% in 2025.
Edwards' ambitions to diversify into minimally invasive medical technologies place the firm in direct competition with much larger competitors, such as Medtronic and Abbott, which can easily bid up prices for emerging technologies that Edwards couldn't match.
|
Metric
|
EW
|
MDT
|
ABT
|
|---|---|---|---|
Price/Earnings (Normalized) | 30.32 | 15.27 | 18.37 |
Price/Book Value | 4.63 | 2.20 | 3.27 |
Price/Sales | 7.61 | 2.96 | 3.62 |
Price/Cash Flow | 30.15 | 12.40 | 15.44 |
|
Metric
|
EW
|
MDT
|
ABT
|
|---|---|---|---|
Quick Ratio | 3.45 | 1.29 | 0.97 |
Current Ratio | 4.52 | 2.07 | 1.38 |
Interest Coverage | — | 10.12 | 10.40 |
|
Metric
|
EW
|
MDT
|
ABT
|
|---|---|---|---|
Return on Assets (Normalized) | 12.05% | 8.31% | 9.71% |
Return on Equity (Normalized) | 15.67% | 15.59% | 17.95% |
Return on Invested Capital (Normalized) | 13.78% | 10.57% | 13.03% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|>CCG>rN | LOCK|!M<d | $167B | |||
| Medtronic PLC
MDT
| LOCK|%#f@$g | LOCK|%!G% | $111B | |||
| Stryker Corp
SYK
| LOCK|m?g$#Jg | LOCK|kC | $105B | |||
| Boston Scientific Corp
BSX
| LOCK|Z?@^>^^ | LOCK|<rD# | $63B | |||
| DexCom Inc
DXCM
| LOCK|q#N&?<$ | LOCK|&Dt! | $33B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|<Csthv | LOCK|WcW | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|>l | LOCK|>q | $23B | |||
| Steris PLC
STE
| LOCK|vktLNZ | LOCK|zdls# | $20B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|$CDsHJ@@ | LOCK|K% | $17B |
United States